Search research articles
Contact Us
Filters
Showing results (231-240 of 245) with videos related to
Page
of 25
Sort By:
Targeted Oncology
|
May 13, 2016
An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib
J Mateo, V Moreno, A Gupta, et al.
Revista De Calidad Asistencial : Organo De La Sociedad Espanola De Calidad Asistencial
|
August 18, 2014
[Out of hospital emergencies towards a safety culture]
M I Cano-del Pozo, B Obón-Azuara, M Valderrama-Rodríguez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 18, 2022
Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations
Z Kuzbari, C Bandlamudi, C Loveday, et al.
ESMO Open
|
November 7, 2025
Genomic actionability and matched targeted therapy in a decade-long institutional precision medicine program for solid tumors
R Dienstmann, A Vivancos, P Nuciforo, et al.
ESMO Open
|
September 10, 2024
Durable benefit from poly(ADP-ribose) polymerase inhibitors in metastatic prostate cancer in routine practice: biomarker associations and implications for optimal clinical next-generation sequencing testing
D Triner, R P Graf, R W Madison, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 21, 2025
Corrigendum to "Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group": [Ann Oncol 35 (2024) 588-606]
M F Mosele, C B Westphalen, A Stenzinger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 4, 2024
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group
M F Mosele, C B Westphalen, A Stenzinger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 28, 2020
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
F Mosele, J Remon, J Mateo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 26, 2024
The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development
C B Westphalen, D Martins-Branco, J R Beal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 7, 2024
ESMO Recommendations on clinical reporting of genomic test results for solid cancers
J van de Haar, P Roepman, F Andre, et al.
Page
of 25
Search research articles
Search
Showing results (231-240 of 245) with videos related to
Sort By:
Page
of 25
Targeted Oncology
|
May 13, 2016
An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib
J Mateo, V Moreno, A Gupta, et al.
Revista De Calidad Asistencial : Organo De La Sociedad Espanola De Calidad Asistencial
|
August 18, 2014
[Out of hospital emergencies towards a safety culture]
M I Cano-del Pozo, B Obón-Azuara, M Valderrama-Rodríguez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 18, 2022
Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations
Z Kuzbari, C Bandlamudi, C Loveday, et al.
ESMO Open
|
November 7, 2025
Genomic actionability and matched targeted therapy in a decade-long institutional precision medicine program for solid tumors
R Dienstmann, A Vivancos, P Nuciforo, et al.
ESMO Open
|
September 10, 2024
Durable benefit from poly(ADP-ribose) polymerase inhibitors in metastatic prostate cancer in routine practice: biomarker associations and implications for optimal clinical next-generation sequencing testing
D Triner, R P Graf, R W Madison, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 21, 2025
Corrigendum to "Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group": [Ann Oncol 35 (2024) 588-606]
M F Mosele, C B Westphalen, A Stenzinger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 4, 2024
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group
M F Mosele, C B Westphalen, A Stenzinger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 28, 2020
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
F Mosele, J Remon, J Mateo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 26, 2024
The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development
C B Westphalen, D Martins-Branco, J R Beal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 7, 2024
ESMO Recommendations on clinical reporting of genomic test results for solid cancers
J van de Haar, P Roepman, F Andre, et al.
Page
of 25